Keynote: Louis Pasteur and the microbiological risk (Patrick Berche) |
|
|
|
|
Book presentation (René Courcol) |
|
|
|
|
Parallell session 1: Biosafety of gene therapy (general) |
|
|
|
|
- Replication-competent viruses in cancer gene therapy: biosafety considerations (Rob C. Hoeben) |
|
|
|
|
- Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Gene Therapy (Danielle Horst) |
|
|
|
|
- Environmental risk assessment for gene and cell therapy products: critical issues for CT and MA applications (Ursula Jenal) |
|
|
|
|
Parallell session 2: Working with plants or animals (general) |
|
|
|
|
- EPPO and ensuring plant health in a world without borders (Françoise Petter) |
|
|
|
|
- Taking stock of the environmental risk assessment of GM plants (Patrick Rüdelsheim) |
|
|
|
|
- Keeping them in or out? Control of aerosols in loose housed versus caged laboratory research animals for HPAI studies (Henriette Schubert) |
|
|
|
|
Company prentations (general) |
|
|
|
|
- Risk reduction and best energy savings by membrane air filtration technology for biosafety environments (AAF-Luftechnik) |
|
|
|
|
- Biowaste management: several technologies ... just choose the most convenient for your project! (Actini SAS) |
|
|
|
|
Selection criteria for Effluent Decontamination Systems (PRI Bio) |
|
|
|
|
Best practices and future threaths (Guy Collyer sponsored by BioSAFE engineering) |
|
|
|
|
Biological Safety Cabinets: Simulation and Quantifying of Airflow Perturbation Caused by Personnel Activities presentation (berner international) |
|
|
|
|
Chris Collins Lecture: WHO biosafety manual revision - concept and consequences |
|
|
|
|
Session 3 - Applied biosafety (general) |
|
|
|
|
Impact of EU Biocides Regulation to Biosafety (Heather Sheeley) |
|
|
|
|
Validation of high containment facilities to prove biosafety (Evelien Kampert) |
|
|
|
|
Alternatives to heath inactivation - challenges in demonstrating effectivity (Claudia Bagutti) |
|
|
|
|